Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2008

View Archived Issues

Studies show surfen to be a heparan sulfate antagonist

Merck & Co reports results from studies with cathepsin K inhibitor odanacatib

Recent patents report novel therapeutic agents for HCV infection

New anticancer agents described in recent patents

Kaken launches new formulation Adofeed Pap 80 mg in Japan

Novel agents for respiratory and allergic disorders disclosed in recent patent literature

New antiviral drug company formed, Cocrystal Discovery

Omrix enrolls initial 90 patients for interim analysis in Fibrin Pad phase II trial

Paion presents update on phase I CNS-7056 study

SciClone presents promising phase II results for SCV-07 in hepatitis C

Clinical data for rheumatoid arthritis drug candidate VEL-0230 presented

Akesis expands preclinical safety program for AKP-020

Novel TNF-alpha antagonists developed at Ensemble Discovery

Athersys provides update on ATHX-105 development and results of recent studies

Preliminary results for AMG-386 in combination with other antiangiogenic agents in solid tumors

Belinostat in combination with carboplatin and paclitaxel evaluated in phase I/II cancer studies

Cornerstone initiates CPI-613 trial for the treatment of cancer

Metabasis initiates MB-07803 trial in patients with type 2 diabetes

Oramed commences phase IIa oral insulin trials in patients with type 1 diabetes

PolyMedix starts dosing in phase I novel anticoagulant antagonist trial

Baxter initiates phase III Gammagard Liquid trial for the treatment of AD

MAA for lacosamide in diabetic neuropathic pain withdrawn; product launched in E.U. for seizures

CHMP issues positive opinion for Kuvan for hyperphenylalaninemia

Abstral receives U.K. marketing authorization for breakthrough cancer pain

Aveo initiates first SCH-900105 trial in patients with solid tumors and lymphomas

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 8, 2025.
House passes H.R. 1, restoring R&D tax cuts
BioWorld MedTech
The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
Exercise-mimicking compound offers alternative to GLP-1 therapies
BioWorld
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
With surface mimicry, molecular glues shed hairpin need
BioWorld Science
Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...